- Patients with constipation treated with linaclotide (Linzess) are more likely to report bowel movement (BM) satisfaction than those undergoing other treatments.
Why this matters
- Understanding patient perceptions of treatment effects may help clinicians manage expectations and inform clinical decision making.
- Researchers studied BM diaries completed by patients with either irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (N=1786; mean age, 46.8 years; 94.2% women; 83.3% white; BMs reported, 26,524), using logistic regression to analyze relationships among stool consistency, medication use, and BM satisfaction.
- They classified BMs as loose or watery stools (LoWS), hard or lumpy stools (HoLS), or intermediate (neither LoWS nor HoLS).
- Funding: Allergan; Ironwood Pharmaceuticals.
- Overall BM satisfaction was highest for intermediate stools (61.2%), followed by LoWS (51.2%) and HoLS (19.4%).
- Treatment with linaclotide was associated with higher odds of patient-reported BM satisfaction than treatment with other medications (OR, 1.23; P=.027).
- Results may not apply to uninsured and older populations.
- The study did not assess other factors affecting BM satisfaction, such as straining, urgency, or sense of complete evacuation.